Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar rocknpopstocks (< 20) Submitted: 3/11/2011 12:51:19 PM : Outperform Start Price: $1.57 DYAX Score: +7.82

Should get some play.

Featured Broker Partners


Advertisement